Micrometastatic Cancer Cells in Lymph Nodes, Bone Marrow, and Blood Clinical Significance and Biologic Implications

被引:64
作者
Leong, Stanley P. L. [1 ,2 ,3 ]
Tseng, William W. [4 ]
机构
[1] Calif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Melanoma Program, San Francisco, CA 94115 USA
[2] Sutter Pacific Med Fdn, San Francisco, CA 94115 USA
[3] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA
关键词
cancer metastasis; CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; AMERICAN JOINT COMMITTEE; BREAST-CANCER; SENTINEL-NODE; MELANOMA PATIENTS; METASTATIC MELANOMA; PROGNOSTIC-SIGNIFICANCE; FREE SURVIVAL; MOLECULAR-DETECTION;
D O I
10.3322/caac.21217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer metastasis may be regarded as a progressive process from its inception in the primary tumor microenvironment to distant sites by way of the lymphovascular system. Although this type of tumor dissemination often occurs in an orderly fashion via the sentinel lymph node ( SLN), acting as a possible gateway to the regional lymph nodes, bone marrow, and peripheral blood and ultimately to distant metastatic sites, this is not a general rule as tumor cells may enter the blood and spread to distant sites, bypassing the SLN. Methods of detecting micrometastatic cancer cells in the SLN, bone marrow, and peripheral blood of patients have been established. Patients with cancer cells in their SLN, bone marrow, or peripheral blood have worse clinical outcomes than patients with no evidence of spread to these compartments. The presence of these cells also has important biologic implications for disease progression and the clinician's understanding of the process of cancer metastasis. Further characterization of these micrometastatic cancer cells at each stage and site of metastasis is needed to design novel selective therapies for a more "personalized" treatment. (C) 2014 American Cancer Society.
引用
收藏
页码:196 / 206
页数:11
相关论文
共 119 条
[1]  
Alix-Panabieres Catherine, 2012, Recent Results Cancer Res, V195, P69, DOI 10.1007/978-3-642-28160-0_6
[2]  
Amerasekera S, 2004, J BUON, V9, P465
[3]  
[Anonymous], ARCH SURG
[4]  
[Anonymous], 2010, AJCC Cancer Staging Manual, V7th, P347
[5]   The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival [J].
Baehner, Frederick L. ;
Li, Rui ;
Jenkins, Tyler ;
Hwang, Jimmy ;
Kashani-Sabet, Mohammed ;
Allen, Robert E. ;
Leong, Stanley P. L. .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (03) :1034-1042
[6]   Update on the Melanoma Staging System: The Importance of Sentinel Node Staging and Primary Tumor Mitotic Rate [J].
Balch, Charles M. ;
Gershenwald, Jeffrey E. ;
Soong, Seng-Jaw ;
Thompson, John F. .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (04) :379-385
[7]   Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases [J].
Balch, Charles M. ;
Gershenwald, Jeffrey E. ;
Soong, Seng-jaw ;
Thompson, John F. ;
Ding, Shouluan ;
Byrd, David R. ;
Cascinelli, Natale ;
Cochran, Alistair J. ;
Coit, Daniel G. ;
Eggermont, Alexander M. ;
Johnson, Timothy ;
Kirkwood, John M. ;
Leong, Stanley P. ;
McMasters, Kelly M. ;
Mihm, Martin C., Jr. ;
Morton, Donald L. ;
Ross, Merrick I. ;
Sondak, Vernon K. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2452-2459
[8]  
Balch CM, 2003, ANN SURG, V238, P549
[9]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[10]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648